^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    KC1036

    i
    Other names: KC1036
    Company:
    Konruns Pharma
    Drug class:
    FLT3 inhibitor, VEGFR-2 inhibitor, Tyrosine kinase inhibitor, AXL inhibitor
    Related drugs:
    1m
    To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors (clinicaltrials.gov)
    P1/2, N=133, Recruiting, Beijing Konruns Pharmaceutical Co., Ltd. | Trial completion date: Apr 2025 --> Dec 2025 | Trial primary completion date: Apr 2024 --> Oct 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    KC1036
    1m
    A Study of KC1036 in Patients with Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=207, Recruiting, Beijing Konruns Pharmaceutical Co., Ltd. | Trial completion date: Jul 2024 --> Dec 2025 | Trial primary completion date: Jul 2023 --> Oct 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    KC1036
    3ms
    A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma (clinicaltrials.gov)
    P2, N=30, Recruiting, Beijing Konruns Pharmaceutical Co., Ltd.
    New P2 trial • Metastases
    |
    KC1036
    9ms
    A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer (clinicaltrials.gov)
    P3, N=490, Recruiting, Beijing Konruns Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    docetaxel • irinotecan • Teysuno (gimeracil/oteracil/tegafur) • KC1036
    11ms
    A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer (clinicaltrials.gov)
    P3, N=490, Not yet recruiting, Beijing Konruns Pharmaceutical Co., Ltd.
    New P3 trial • Metastases
    |
    docetaxel • irinotecan • Teysuno (gimeracil/oteracil/tegafur) • KC1036
    1year
    A Food Effect Study of KC1036 in Healthy Subjects (clinicaltrials.gov)
    P1, N=12, Completed, Beijing Konruns Pharmaceutical Co., Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    KC1036
    over1year
    Establishment and characterization of a novel lung adenocarcinoma cell line HX-JCJ harboring MET ex14 skipping mutation (ESMO 2023)
    Results Drug screen showed that this cell line was extremely sensitive to KC1036 (IC50=4.8nm), which is a home-made small molecule inhibitor with strong anti-MET and anti-angiogensis activity. Conclusions In conclusion, we successfully established a novel NSCLC cell line (HX-JCJ) harboring MET ex14 skipping mutation from the primary tumor tissue, which may provide a promising cell model for further MET relevant research.
    Preclinical
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET exon 14 mutation • MET mutation
    |
    KC1036